Müllertz S
Biochem J. 1974 Nov;143(2):273-83. doi: 10.1042/bj1430273.
Urokinase-activated human plasma was studied by gel electrophoresis, gel filtration, crossed immunoelectrophoresis and electroimmunoassay with specific antibodies and by assay of esterase and protease activity of isolated fractions. Urokinase induced the formation of different components with plasminogen+plasmin antigenicity. At low concentrations of urokinase, a component with a K(D) value of 0.18 by gel filtration and post beta(1) mobility by gel electrophoresis was detected. The isolated component had no enzyme or plasminogen activity. In this plasma sample fibrinogen was not degraded for 10h, but when fibrin was formed, by addition of thrombin, fibrin was quickly lysed, and simultaneously a component with a K(D) value of 0 and alpha(2) mobility appeared, which was probably plasmin in a complex with alpha(2) macroglobulin. This complex showed both esterase and protease activity. After gel filtration with lysine buffer of the clotted and lysed plasma another two components were observed with about the same K(D) value by gel filtration as plasminogen (0.35), but beta(1) and gamma mobilities by gel electrophoresis. They appeared to be modified plasminogen molecules, and possibly plasmin with gamma mobility. Similar processes occurred without fibrin at higher urokinase concentrations. Here a relatively slow degradation of fibrinogen was correlated to the appearance of the plasmin-alpha(2) macroglobulin complex. The fibrin surface appeared to catalyse the ultimate production of active plasmin with a subsequent preferential degradation of fibrin and the formation of a plasmin-alpha(2) macroglobulin complex. The gel filtration and electrophoresis of the plasma protease inhibitors, alpha(1) antitrypsin, inter-alpha-inhibitor, antithrombin III, and C(1)-esterase inhibitor indicated that any complex between plasmin and these inhibitors was completely dissociated. The beta(1) and post beta(1) components appear to lack correlates among components occurring in purified preparations of plasminogen and plasmin.
采用凝胶电泳、凝胶过滤、交叉免疫电泳以及用特异性抗体进行的电免疫测定法,并通过对分离组分的酯酶和蛋白酶活性进行测定,对尿激酶激活的人血浆进行了研究。尿激酶诱导形成了具有纤溶酶原 + 纤溶酶抗原性的不同组分。在低浓度尿激酶时,通过凝胶过滤检测到一种K(D)值为0.18且通过凝胶电泳具有β(1)迁移率的组分。分离出的该组分没有酶活性或纤溶酶原活性。在该血浆样本中,纤维蛋白原在10小时内未被降解,但当加入凝血酶形成纤维蛋白时,纤维蛋白迅速溶解,同时出现了一种K(D)值为0且具有α(2)迁移率的组分,其可能是与α(2)巨球蛋白形成复合物的纤溶酶。该复合物同时具有酯酶和蛋白酶活性。在用赖氨酸缓冲液对凝结并溶解的血浆进行凝胶过滤后,观察到另外两种组分,通过凝胶过滤其K(D)值与纤溶酶原大致相同(0.35),但通过凝胶电泳具有β(1)和γ迁移率。它们似乎是修饰的纤溶酶原分子,也可能是具有γ迁移率的纤溶酶。在较高尿激酶浓度下,即使没有纤维蛋白也会发生类似过程。此处纤维蛋白原的相对缓慢降解与纤溶酶 - α(2)巨球蛋白复合物的出现相关。纤维蛋白表面似乎催化了活性纤溶酶的最终产生,随后纤维蛋白被优先降解并形成纤溶酶 - α(2)巨球蛋白复合物。对血浆蛋白酶抑制剂α(1)抗胰蛋白酶、α - 间抑制剂、抗凝血酶III和C(1)酯酶抑制剂进行凝胶过滤和电泳表明,纤溶酶与这些抑制剂之间的任何复合物都完全解离。β(1)和β(1)后组分似乎在纤溶酶原和纤溶酶的纯化制剂中出现的组分之间缺乏相关性。